Navigating Uncertainty: Moderna's Future Pipeline & Team Impact

Just wanted to open up a discussion about what feels like a period of significant re-evaluation at Moderna. Beyond the public narratives about vaccine funding (which are definitely relevant), I'm trying to understand the internal implications. There's been talk, almost whispers, about certain programs being de-prioritized or seeing reduced investment. I haven't experienced any direct impact myself, nor have I seen official layoff notices, but the strategic shifts feel palpable. It makes you wonder about the long-term vision and how it translates to day-to-day roles and team structures. Is anyone else seeing shifts in project scope or team composition that seem to point towards future restructuring or talent adjustments? Trying to get a clearer picture beyond the headlines and figure out if this is a widespread feeling or isolated to certain departments. Any insights on how leadership is framing these changes internally would be appreciated.